Epkinly Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to rising incidence of non-hodgkin lymphoma, limitations of conventional chemotherapy, advancement in monoclonal antibody research, increased approvals for targeted oncology drugs, unmet needs in relapsed cancer treatment.

The growth in the forecast period can be attributed to growing adoption of immuno-oncology therapies, expanding clinical indications for bispecific antibodies, improved patient outcomes data, increasing oncology healthcare spending, expansion of specialty cancer centers. Major trends in the forecast period include bispecific antibody immunotherapies, expansion of t-cell engaging oncology drugs, focus on relapsed and refractory lymphomas, subcutaneous oncology drug administration, personalized hematologic cancer treatment.

The growing demand for targeted therapies is expected to drive the expansion of the epkinly market in the coming years. Targeted therapies are precise treatments that block specific molecules driving disease, particularly cancers, while minimizing side effects compared to traditional therapies. Their adoption is increasing due to their ability to provide more effective, personalized treatment with fewer adverse effects. Epkinly (epcoritamab) is used in targeted therapy for relapsed or refractory B-cell non-Hodgkin lymphoma by binding CD3 on T cells and CD20 on B cells, directing the immune system to destroy cancerous B cells. For example, in October 2024, the National Health Service, a UK-based government department, reported that in 2023/24, 14.5% of hormone replacement therapy (HRT) items were associated with an HRT prescription prepayment certificate (PPC). By June 2024, this proportion had risen to 21%, compared to 9.7% in June 2023. Therefore, the rising demand for targeted therapies is supporting the growth of the epkinly market.

A key trend in the epkinly market is obtaining regulatory approvals for innovative therapies, such as bispecific antibody therapies, to improve treatment efficacy and expand therapeutic options. Bispecific antibody therapies are immunotherapies engineered to bind simultaneously to two different antigens or targets. For instance, in June 2024, AbbVie Inc., a US-based biotechnology company, received FDA approval for EPKINLY (epcoritamab-bysp), the first bispecific antibody for adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This therapy engages the immune system by targeting CD20 and CD3, achieving an overall response rate of 82% in clinical trials. Administered subcutaneously with a step-up dosing regimen, EPKINLY provides a new treatment option for patients with limited alternatives. This approval represents a significant advancement in follicular lymphoma management, offering hope for improved patient outcomes.

In June 2024, AbbVie Inc. partnered with Genmab A/S to jointly develop and commercialize innovative bispecific antibody therapies, including epcoritamab. By combining Genmab’s advanced antibody technology with AbbVie’s clinical expertise, the partnership aims to expand treatment options. Genmab A/S, a Denmark-based biotechnology company, is actively involved in the development and commercialization of epkinly (epcoritamab), a bispecific antibody therapy.

Major companies operating in the epkinly market are AbbVie Inc., Genmab A/S.

North America was the largest region in the epkinly market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the epkinly market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the epkinly market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the epkinly market by increasing costs associated with imported biologic raw materials, specialized antibodies, and advanced manufacturing equipment. These added costs have affected pricing and supply consistency, particularly across North America and Europe where biologic imports are common. Hospital and specialty pharmacy segments are most affected due to high handling and storage requirements. At the same time, tariffs are encouraging domestic biologics manufacturing and localized supply chains, supporting long-term production stability and innovation.

The epkinly market research report is one of a series of new reports that provides epkinly market statistics, including epkinly industry global market size, regional shares, competitors with a epkinly market share, detailed epkinly market segments, market trends and opportunities, and any further data you may need to thrive in the epkinly industry. This epkinly market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Epkinly (generic name epcoritamab) is a monoclonal antibody used to treat certain cancers, particularly relapsed or refractory B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL) and other non-Hodgkin lymphoma (NHL) subtypes. It works by binding to CD3 on T cells and CD20 on B cells, enabling the immune system to recognize and destroy cancerous cells.

The primary indications for epkinly are relapsed or refractory diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBL), and indolent lymphoma. Relapsed or refractory DLBCL refers to disease that returns after initial treatment. The drug is available in multiple routes of administration, including intravenous (IV) and subcutaneous (SC), and is distributed through hospital pharmacies, retail pharmacies, specialty pharmacies, and online pharmacies.

The epkinly market consists of sales of products including rituxan (rituximab), polivy (polatuzumab vedotin), kymriah (tisagenlecleucel), yescarta (axicabtagene ciloleucel), and gazyva (obinutuzumab). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.